JW PHARMACEUTICAL CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,400 KRW | +2.01% |
|
+4.29% | -14.49% |
| Mar. 14 | JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 22 | CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 505,678 | 419,688 | 828,523 | 708,774 | - |
| Enterprise Value (EV) 2 | 505.7 | 541.3 | 828.5 | 812.5 | 797.3 |
| P/E ratio | -543 x | 13.8 x | 23.3 x | 9.95 x | 10.1 x |
| Yield | - | 2.04% | - | 1.19% | 1.19% |
| Capitalization / Revenue | - | 0.61 x | 1.1 x | 0.86 x | 0.8 x |
| EV / Revenue | - | 0.79 x | 1.1 x | 0.98 x | 0.9 x |
| EV / EBITDA | - | 6.78 x | 6.74 x | 6.57 x | 6.4 x |
| EV / FCF | - | 11.6 x | - | 23 x | 23.9 x |
| FCF Yield | - | 8.66% | - | 4.34% | 4.19% |
| Price to Book | - | 1.83 x | - | 2.31 x | 1.93 x |
| Nbr of stocks (in thousands) | 23,208 | 23,195 | 23,328 | 23,328 | - |
| Reference price 3 | 21,702 | 17,990 | 35,550 | 30,400 | 30,400 |
| Announcement Date | 3/21/22 | 2/8/23 | 2/5/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 684.4 | 750 | 827.5 | 890 |
| EBITDA 1 | - | 79.8 | 122.9 | 123.6 | 124.6 |
| EBIT 1 | - | 64.44 | 99.58 | 105.6 | 105.8 |
| Operating Margin | - | 9.42% | 13.28% | 12.76% | 11.88% |
| Earnings before Tax (EBT) 1 | - | 46.41 | 51.61 | 95 | 91 |
| Net income 1 | -0.9162 | 33.55 | 34.84 | 73.5 | 72.5 |
| Net margin | - | 4.9% | 4.65% | 8.88% | 8.15% |
| EPS 2 | -39.98 | 1,305 | 1,529 | 3,056 | 3,014 |
| Free Cash Flow 3 | - | 46,851 | - | 35,250 | 33,400 |
| FCF margin | - | 6,846.09% | - | 4,259.99% | 3,752.95% |
| FCF Conversion (EBITDA) | - | 58,712.94% | - | 28,511.73% | 26,805.78% |
| FCF Conversion (Net income) | - | 139,647.45% | - | 47,959.18% | 46,068.97% |
| Dividend per Share 2 | - | 367.6 | - | 361.3 | 361.3 |
| Announcement Date | 3/21/22 | 2/8/23 | 2/5/24 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 156.3 | 165 | 169.8 | 193.2 | 173.4 | 185.9 | 184.2 | 205 | 186.4 | 205.2 | 217 | 218 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 13.32 | 9.403 | 11.56 | 30.16 | 20.32 | 20.57 | 26.11 | 33.3 | 23.95 | 25.05 | 26.6 | 30.7 |
| Operating Margin | 8.52% | 5.7% | 6.8% | 15.62% | 11.72% | 11.07% | 14.17% | 16.24% | 12.85% | 12.21% | 12.26% | 14.08% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | - | - | - | - | - | 13.08 | -17.91 | 24.96 | 19.5 | 19.2 | 20.1 | 14.1 |
| Net margin | - | - | - | - | - | 7.03% | -9.72% | 12.18% | 10.46% | 9.36% | 9.26% | 6.47% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/16/22 | 8/16/22 | 11/15/22 | 2/8/23 | 5/15/23 | 8/14/23 | 11/14/23 | 2/5/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 122 | - | 104 | 88.6 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.524 x | - | 0.8388 x | 0.7107 x |
| Free Cash Flow 2 | - | 46,851 | - | 35,250 | 33,400 |
| ROE (net income / shareholders' equity) | - | 16.1% | 14.3% | 22.2% | 18.1% |
| ROA (Net income/ Total Assets) | - | 4.73% | - | 9.5% | 8.5% |
| Assets 1 | - | 708.6 | - | 773.7 | 852.9 |
| Book Value Per Share 3 | - | 9,813 | - | 13,153 | 15,724 |
| Cash Flow per Share | - | 2,467 | - | - | - |
| Capex 1 | - | 9.91 | - | 22.9 | 24.5 |
| Capex / Sales | - | 1.45% | - | 2.77% | 2.76% |
| Announcement Date | 3/21/22 | 2/8/23 | 2/5/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
30,400
KRW
Average target price
41,667
KRW
Spread / Average Target
+37.06%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.49% | 515M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A001060 Stock
- Financials JW Pharmaceutical Corporation
